Novavax Inc (NVAX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Novavax Inc (NVAX) has a cash flow conversion efficiency ratio of 0.224x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.42 Million) by net assets ($-144.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Novavax Inc balance sheet quality to measure how much of total assets are equity-financed.
Novavax Inc - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Novavax Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Novavax Inc (NVAX) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Novavax Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Novavax Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Anhui Hwasu Co.Ltd.
SHG:600935
|
N/A |
|
Afry AB
ST:AFRY
|
-0.006x |
|
Hotai Finance Corp
TW:6592
|
-0.067x |
|
Dogan Sirketler Grubu Holding AS
IS:DOHOL
|
0.116x |
|
Beijing Jingwei Hirain Technologies Co. Ltd. A
SHG:688326
|
-0.001x |
|
Liquidity Services Inc
NASDAQ:LQDT
|
0.133x |
|
Jade Biosciences, Inc.
NASDAQ:JBIO
|
-0.081x |
|
Titagarh Rail Systems Limited
NSE:TITAGARH
|
0.073x |
Annual Cash Flow Conversion Efficiency for Novavax Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of Novavax Inc from 1996 to 2025. For the full company profile with market capitalisation and key ratios, see Novavax Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-127.75 Million | $-244.63 Million | 1.915x | +1268.96% |
| 2024-12-31 | $-623.84 Million | $-87.26 Million | 0.140x | -85.95% |
| 2023-12-31 | $-716.93 Million | $-713.97 Million | 0.996x | +51.82% |
| 2022-12-31 | $-634.08 Million | $-415.94 Million | 0.656x | +171.43% |
| 2021-12-31 | $-351.67 Million | $322.95 Million | -0.918x | -1253.93% |
| 2020-12-31 | $627.21 Million | $-42.54 Million | -0.068x | -109.23% |
| 2019-12-31 | $-186.02 Million | $-136.62 Million | 0.734x | -33.27% |
| 2018-12-31 | $-167.94 Million | $-184.82 Million | 1.101x | -19.27% |
| 2017-12-31 | $-101.73 Million | $-138.70 Million | 1.363x | -97.04% |
| 2016-12-31 | $-5.55 Million | $-255.47 Million | 46.063x | +10791.80% |
| 2015-12-31 | $292.67 Million | $-126.09 Million | -0.431x | -47.62% |
| 2014-12-31 | $229.62 Million | $-67.01 Million | -0.292x | -30.77% |
| 2013-12-31 | $203.23 Million | $-45.36 Million | -0.223x | +1.76% |
| 2012-12-31 | $80.24 Million | $-18.23 Million | -0.227x | +48.23% |
| 2011-12-31 | $53.85 Million | $-23.63 Million | -0.439x | +21.13% |
| 2010-12-31 | $59.05 Million | $-32.85 Million | -0.556x | -26.19% |
| 2009-12-31 | $74.47 Million | $-32.83 Million | -0.441x | +17.50% |
| 2008-12-31 | $45.49 Million | $-24.31 Million | -0.534x | -26.03% |
| 2007-12-31 | $63.06 Million | $-26.74 Million | -0.424x | -169.14% |
| 2006-12-31 | $94.00 Million | $-14.81 Million | -0.158x | -34.67% |
| 2005-12-31 | $49.65 Million | $-5.81 Million | -0.117x | +87.06% |
| 2004-12-31 | $33.28 Million | $-30.10 Million | -0.904x | -85.26% |
| 2003-12-31 | $35.94 Million | $-17.55 Million | -0.488x | +81.29% |
| 2002-12-31 | $8.07 Million | $-21.07 Million | -2.609x | -1471.21% |
| 2001-12-31 | $27.49 Million | $-4.57 Million | -0.166x | +47.38% |
| 2000-12-31 | $31.82 Million | $-10.04 Million | -0.316x | +76.12% |
| 1999-12-31 | $2.80 Million | $-3.70 Million | -1.321x | -10.12% |
| 1998-12-31 | $3.00 Million | $-3.60 Million | -1.200x | -85.71% |
| 1997-12-31 | $6.50 Million | $-4.20 Million | -0.646x | +0.14% |
| 1996-12-31 | $5.10 Million | $-3.30 Million | -0.647x | -- |
About Novavax Inc
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Com… Read more